Original Article

Disability-Adjusted Life Years (DALY) for Cancers in Iran, 1990 to 2016: Review of Findings from the Global Burden of Disease Study


Background: Cancer with 13% of all deaths is the third leading cause of mortality in Iran. We aimed to assess the burden of cancer in Iran by acquiring data from the Global Burden of Disease (GBD) study.

Methods: This study was conducted on the DALY approach to examine the cancer burden in Iran from 1990 to 2016. A list of all cancers was extracted using the International Classification of Disease, tenth revision (ICD-10). Then, the cancer burden was assessed based on the type of cancer. The Percentage change (PC) by Daly’s number and age-standardized DALY rate (ASDR) was estimated. The cause of PC on the DALYs number from cancer was analyzed, and the share of every variable was determined.

Results: In 2016, cancer caused 781.5 and 564 thousand DALYs for men and women, respectively. In all years, the DALYs number of cancer is higher in men than women. From 1990 to 2016, leukemia, stomach, tracheal, bronchus and lung (TBL) cancers were among the leading causes of cancer burden in Iran. The highest increase in PC of cancer DALYs from 1990 to 2016 happened by multiple myeloma with 302.4% and breast with 283.7%. The lowest increase occurred by Hodgkin lymphoma (-2.1%) and leukemia (18.2%).

Conclusion: Cancers have grown more than doubled in terms of DALYs from 1990 to 2016. The majority of DALYs were due to Years of Life Lost, suggesting the need for prevention, early detection, and screening programs.

1. Ferlay J, Colombet M, Soerjomataram I, et al (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 144:1941-1953.
2. Arnold M, Pandeya N, Byrnes G, et al (2015). Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol, 16:36-46.
3. Bray F, Jemal A, Grey N, et al (2012). Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol, 13:790-801.
4. McKenna MT, Michaud CM, Murray CJ, et al (2005). Assessing the burden of disease in the United States using disability-adjusted life years. Am J Prev Med, 28:415-423.
5. WHO (2017). WHO methods and data sources for global burden of disease estimates 2000-2015. Department of Information, Evi dence and Researc h
WHO, Geneva.
6. Lopez A, Mathers C, Ezzati M, et al (2006). Global Burden of Disease and Risk Factors: A copublication of Oxford University Press and The World Bank.
7. Melaku YA, Appleton SL, Gill TK, et al (2018). Incidence, prevalence, mortality, disability-adjusted life years and risk factors of cancer in Australia and comparison with OECD countries, 1990–2015: findings from the Global Burden of Disease Study 2015. Cancer Epidemiol, 52:43-54.
8. Fitzmaurice C, Allen C, Barber RM, et al (2017). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol, 3:524-548.
9. Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al (2012). Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet, 380:1840-1850.
10. Pham T-M, Kubo T, Fujino Y, et al (2011). Disability-adjusted life years (DALY) for cancer in Japan in 2000. J Epidemiol, 21:309-312.
11. Shimada K, Kai M (2015). Calculating disability-adjusted life years (DALY) as a measure of excess cancer risk following radiation exposure. J Radiol Prot, 35:763-75.
12. (2018) International Monetary Fund, International Financial Statistics and data files. 2016. Available from: https://data.worldbank.org/indicator/SP.POP.TOTL
13. Majidi A, Ghiasvand R, Hadji M, et al (2015). Priority setting for improvement of cervical cancer prevention in Iran. Int J Health Policy Manag, 5:225-32.
14. Nahvijou A, Daroudi R, Tahmasebi M, et al (2016). Cost-effectiveness of different cervical screening strategies in Islamic Republic of Iran: a middle-income country with a low incidence rate of cervical cancer. PLoS One, 11:e0156705.
15. Fitzmaurice C, Dicker D, Pain A, et al (2015). The global burden of cancer 2013. JAMA Oncol, 1:505-527.
16. Moraga-Serrano PE (2018). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol, 4:1553-1568.
17. Sierra MS, Cueva P, Bravo LE, Forman D (2016). Stomach cancer burden in Central and South America. Cancer Epidemiol, 44 Suppl 1:S62-S73.
18. Kolahdoozan Sh, Sadjadi A, Radmard A.R et al (2010). Five common cancers in Iran. Arch Iran Med, 13:143-6.
19. Sadjadi A, Marjani H, Semnani S, Nasseri-Moghaddam S (2010). Esophageal cancer in Iran: A review. Middle East Journal of Cancer, 1:5-14.
20. Daroudi R, Sari AA, Nahvijou A, et al (2015). The economic burden of breast cancer in Iran. Iran J Public Health, 44:1225-33.
21. Vahdatimanesh Z, Zendehdel K, kbari Sari AA, et al (2017). Economic burden of colorectal cancer in Iran in 2012. Med J Islam Repub Iran, 31:115.
IssueVol 50 No 10 (2021) QRcode
SectionOriginal Article(s)
Disability adjusted life years Global burden of disease Iran Cancer

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Nahvijou A. Disability-Adjusted Life Years (DALY) for Cancers in Iran, 1990 to 2016: Review of Findings from the Global Burden of Disease Study. Iran J Public Health. 2021;50(10):2095-2104.